Reckitt Benckiser, XenoPort deal
XenoPort granted Reckitt an exclusive, worldwide license to develop and commercialize arbaclofen placarbil ( XP19986). XenoPort will have certain rights to negotiate with Reckitt on collaborations for non-addiction indications. Reckitt plans to begin a Phase IIb trial of the transported prodrug of R- baclofen, a GABA B receptor agonist, to treat alcohol use disorders, but could not be reached for a timeline.
XenoPort will receive $20 million cash up front plus an additional $5 million upon the transfer of certain technology and materials to Reckitt. XenoPort will also be eligible for up to $70 million in development and regulatory milestones and up to $50 million in commercial milestones, plus tiered double-digit royalties up to the mid-teens on net U.S. sales and high single-digit royalties on net ex-U.S. sales. ...